[go: up one dir, main page]

ZA909568B - Stabilized solutions of psychotropic agents - Google Patents

Stabilized solutions of psychotropic agents

Info

Publication number
ZA909568B
ZA909568B ZA909568A ZA909568A ZA909568B ZA 909568 B ZA909568 B ZA 909568B ZA 909568 A ZA909568 A ZA 909568A ZA 909568 A ZA909568 A ZA 909568A ZA 909568 B ZA909568 B ZA 909568B
Authority
ZA
South Africa
Prior art keywords
stabilized
methionine
psychotropic agents
stabilized solutions
septiline
Prior art date
Application number
ZA909568A
Other languages
English (en)
Inventor
Petrus Johannes Maria Oetelaar
Johannes Maria Van Den Petrus
Maria Martina Francisc Mentink
Martina Francisca Mentin Maria
Original Assignee
Akzo Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akzo Nv filed Critical Akzo Nv
Publication of ZA909568B publication Critical patent/ZA909568B/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/14Quaternary ammonium compounds, e.g. edrophonium, choline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/26Psychostimulants, e.g. nicotine, cocaine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
ZA909568A 1989-12-06 1990-11-28 Stabilized solutions of psychotropic agents ZA909568B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP89203092 1989-12-06

Publications (1)

Publication Number Publication Date
ZA909568B true ZA909568B (en) 1991-09-25

Family

ID=8202518

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA909568A ZA909568B (en) 1989-12-06 1990-11-28 Stabilized solutions of psychotropic agents

Country Status (15)

Country Link
US (1) US5082864A (xx)
EP (1) EP0431663B1 (xx)
JP (1) JP2977912B2 (xx)
KR (1) KR0185377B1 (xx)
AT (1) ATE99943T1 (xx)
AU (1) AU628768B2 (xx)
CA (1) CA2030773C (xx)
DE (1) DE69005992T2 (xx)
DK (1) DK0431663T3 (xx)
ES (1) ES2062310T3 (xx)
FI (1) FI97689C (xx)
IE (1) IE63985B1 (xx)
NZ (1) NZ236332A (xx)
PT (1) PT96096B (xx)
ZA (1) ZA909568B (xx)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USH1591H (en) * 1992-10-09 1996-09-03 Fulcher; John Preparation of flavor-enhanced reduced calorie fried foods
IL107887A (en) * 1992-12-08 2003-07-06 Ambi Inc Stabilized lanthionine containing bacteriocin compositions
US6197830B1 (en) 1995-09-22 2001-03-06 Bruce M. Frome Method for achieving relief from sympathetically mediated pain
IL121076A (en) * 1996-06-19 2000-10-31 Akzo Nobel Nv Pharmaceutical combinations comprising mirtazapine and one or more selective serotonin reuptake inhibitors
EP0813873B1 (en) * 1996-06-19 2002-02-13 Akzo Nobel N.V. Pharmaceutical composition comprising mirtazapine and one or more selective serotonin reuptake inhibitors
TW587938B (en) * 1997-03-27 2004-05-21 Akzo Nobel Nv Pharmaceutical composition for the treatment and/or prophylaxis of psychotic disorder
BR9909357A (pt) * 1998-04-02 2000-12-12 Akzo Nobel Nv Solução ou suspensão de mirtazapina em mistura com água, formulação farmacêutica compreendendo mirtazapina, e, uso de mirtazapina
US6211171B1 (en) 1998-05-19 2001-04-03 Dalhousie University Use of antidepressants for local analgesia
US6495534B2 (en) * 2000-05-15 2002-12-17 Pharmacia & Upjohn Spa Stabilized aqueous suspensions for parenteral use
US6399310B1 (en) 2001-02-12 2002-06-04 Akzo Nobel N.V. Methods for improving the therapeutic response of humans having major depression and carrying the gene for apolipoprotein E4
US20040106124A1 (en) * 2001-02-12 2004-06-03 Murphy Greer M. Methods for improving the treatment of major depression by genotyping for the gene for apolipoproteine e4 and for improving the terapeutic response of humans having major depression and carrying the gene for apolipoprotein e4
US20030105082A1 (en) * 2001-12-03 2003-06-05 Murphy Greer Marechal Methods for improving the therapeutic response of humans having major depression and carrying the gene for apolipoprotein E4
US20050215552A1 (en) * 2002-05-17 2005-09-29 Gadde Kishore M Method for treating obesity
DK2316456T3 (en) 2003-04-29 2017-09-11 Orexigen Therapeutics Inc Compositions for affecting weight loss comprising an opioid antagonist and bupropion
US7838029B1 (en) * 2003-07-31 2010-11-23 Watson Laboratories, Inc. Mirtazapine solid dosage forms
EP1734955A2 (en) * 2004-01-13 2006-12-27 Duke University Compositions of an anticonvulsant and an antipsychotic drug for affecting weigt loss
US20060039867A1 (en) * 2004-08-20 2006-02-23 Cypress Bioscience, Inc. Method for treating sleep-related breathing disorders with setiptiline
AU2005285040A1 (en) * 2004-09-14 2006-03-23 Molecular Therapeutics, Inc. D-methionine formulation with improved biopharmaceutical properties
US20060122127A1 (en) * 2004-11-17 2006-06-08 Cypress Bioscience, Inc. Methods for reducing the side effects associated with mirtzapine treatment
JP5180092B2 (ja) 2005-11-22 2013-04-10 オレキシジェン・セラピューティクス・インコーポレーテッド インスリン感受性を増すための組成物および方法
EP1981478A2 (en) * 2006-01-17 2008-10-22 Regents of the University of Colorado Central administration of stable formulations of therapeutic agents for cns conditions
US8916195B2 (en) * 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
AU2007319472B2 (en) 2006-11-09 2013-01-17 Nalpropion Pharmaceuticals Llc Methods Of Administering Weight Loss Medications
AU2007319471B9 (en) 2006-11-09 2012-10-04 Nalpropion Pharmaceuticals Llc Layered pharmaceutical formulations comprising an intermediate rapidly dissolving layer
WO2008157094A1 (en) * 2007-06-13 2008-12-24 Cypress Bioscience, Inc. Improving the tolerability of mirtazapine and a second active by using them in combination
CA2725930A1 (en) 2008-05-30 2009-12-30 Orexigen Therapeutics, Inc. Methods for treating visceral fat conditions
ES2762113T3 (es) * 2010-01-11 2020-05-22 Nalpropion Pharmaceuticals Inc Métodos de proporcionar terapia de pérdida de peso en pacientes con depresión mayor
KR20210012056A (ko) 2012-06-06 2021-02-02 오렉시젠 세러퓨틱스 인크. 과체중 및 비만의 치료 방법
KR101652081B1 (ko) 2014-12-30 2016-08-30 김인호 전극보일러 급탕시스템
WO2016138357A1 (en) 2015-02-27 2016-09-01 Kindred Biosciences, Inc. Stimulation of appetite, management of weight loss, and treatment of anorexia in dogs and cats
KR20170001494A (ko) 2015-06-26 2017-01-04 김인호 전극보일러 전류제어시스템
CN108853042B (zh) * 2018-09-20 2021-03-26 北京哈三联科技有限责任公司 一种米氮平冻干口崩片及其制备方法和应用
GR1009883B (el) * 2019-06-07 2020-12-11 Λαμδα Φαρμακευτικα Εργαστηρια Εφαρμοσμενης Ερευνας Και Αναπτυξης Α.Ε. Ποσιμα φαρμακευτικα διαλυματα που περιλαμβανουν υδροχλωρικη νορτριπτυλινη

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2082910A (en) * 1980-08-28 1982-03-17 Berk Pharmaceuticals Ltd Anti-depressant compositions
US4603131A (en) * 1982-04-26 1986-07-29 Bernstein Joel E Method and composition for treating and preventing irritation of the mucous membranes of the nose
DE3247676A1 (de) * 1982-12-23 1984-06-28 A. Nattermann & Cie GmbH, 5000 Köln Galenische form fuer amitriptylinoxid und verfahren zur herstellung

Also Published As

Publication number Publication date
AU628768B2 (en) 1992-09-17
DK0431663T3 (da) 1994-03-07
AU6779890A (en) 1991-06-13
PT96096B (pt) 1998-02-27
DE69005992D1 (de) 1994-02-24
FI906008L (fi) 1991-06-07
CA2030773A1 (en) 1991-06-07
JPH05262651A (ja) 1993-10-12
JP2977912B2 (ja) 1999-11-15
FI97689C (fi) 1997-02-10
EP0431663A1 (en) 1991-06-12
KR910011250A (ko) 1991-08-07
EP0431663B1 (en) 1994-01-12
NZ236332A (en) 1992-07-28
PT96096A (pt) 1991-09-30
US5082864A (en) 1992-01-21
FI97689B (fi) 1996-10-31
DE69005992T2 (de) 1994-05-05
KR0185377B1 (ko) 1999-05-01
FI906008A0 (fi) 1990-12-05
IE63985B1 (en) 1995-06-28
ATE99943T1 (de) 1994-01-15
IE904226A1 (en) 1991-06-19
CA2030773C (en) 2001-07-24
ES2062310T3 (es) 1994-12-16

Similar Documents

Publication Publication Date Title
ZA909568B (en) Stabilized solutions of psychotropic agents
ATE176752T1 (de) Mischkapsel für dentalmassen
DE69629209D1 (de) Getrocknete zubereitung von bluttfaktoren, enthaltend trehalose
EE9500015A (et) Meetod pranoprofeeni stabiliseerimiseks ja pranoprofeeni stabiilne vedelpreparaat
DE50010978D1 (de) Kosmetische Stiftzubereitung
DK0688771T3 (da) Anvendelse af lactamforbindelser som farmaceutiske aktivstoffer
DE60117467D1 (de) Famotidin-injektionen
DE68905414D1 (de) 2-substituierte paraaminophenole und ihre verwendung fuer die faerbung von keratinischen fasern.
HUT57820A (en) Process for stabilizing 3-isothiazolones with mexamethylene tetraamine, stabilized compositions and process for utilizing them
GB2000970A (en) Injectable chloramphenicol composition
KR900009591A (ko) 피리딘-3-퍼옥시카르복실산 모노퍼술페이트
SE7514294L (sv) 4,4'-bis-/2",4"-bis-(diisopropanolamino)-s-triazin-6"-ylamino/-stilben-2,2'-disulfonsyra, dess framstellning och dess anvendning som optiskt vithetsforhojande medel
FI870994A0 (fi) Foerfarande foer framstaellning av stabila, injekterbara farmaceutiska kompositioner, vilka innehaoller 1,4-dihydroxi-5,8-bis/2-(2-hydroxietylamino)etylamino/ antrakinondihydroklorid.
DK0506659T3 (da) Tandtråd med kemoterapeutiske midler.
ES2088280T3 (es) Procedimiento de tincion de fibras queratinicas en medio alcalino que emplea para-aminofenoles sustituidos en posicion 2 en asociacion con el 6- o 7-hidroxiindol y composiciones empleadas en el procedimiento.
DK165689C (da) 1,5-disubstituerede imidazolderivater, fremgangsmaade til fremstilling af saadanne forbindelser, fungicidt praeparat indeholdende saadanne forbindelser samt anvendelse af saadanne forbindelser som fungicider
ATE48616T1 (de) Analoge von hypokalzemischen polypeptiden, welche den kalziumgehalt des koerpers schonen, deren herstellung, deren verwendung als arznei und diese enthaltende zusammensetzungen.
IL96299A (en) Aminomethyl-3-(1- carboxycyclopentyl) propanoic acid derivatives and their preparation
FI903950A0 (fi) Ny komposition.
ATE96424T1 (de) Mit einer cyanogruppe substituierte nitroanilin- farbstoffe.
NZ215671A (en) Larvacidal compositions containing fluorinated cycloalkane carboxanilide derivatives
ITMI921866A1 (it) Uso dell'oxatomide come agente antitosse
DK104691A (da) Cykliske imidatestere til anvendelse som udgangsmateriale ved fremstillling af 1,4-dihydropyrid-5-yl-(cyklisk imidat)estere